HealthCare Global Enterprises Ltd. · NSE:HCG
HealthCare Global Enterprises — Q2 FY2027 Earnings Presentation
33 slides from HealthCare Global Enterprises's earnings presentation, Nov 5, 2026
Slide 1: Intimation letter to stock exchanges on investor presentation
November 05, 2026 National Stock Exchange of India Limited, BSE Limited, Compliance Department, Compliance Department, Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai - 400051, Dalal Street, Mumbai - 400001, Maharashtra, India Maharashtra, India Dear Sir/Madam,
Slide 2: Q2 and H1 FY2027 Results Presentation
HEALTHCARE GLOBAL ENTERPRISES LIMITED Q2 and H1 FY2027 Results Presentation November 5, 2026
Slide 3: Safe Harbor
Safe Harbor This presentation and its contents are confidential and are not for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada, Australia, Japan or any jurisdiction where such distribution is unlawful. This p
Slide 4: Q2 FY27: Performance Update
Q2 FY27: Performance Update Q2 FY27: Performance Update Revenue grew 16% YoY, while Adjusted EBITDA grew 17% YoY, with margins of 19.7% in Q2 FY27 Financial Highlights 7,318 Mn 1,425 Mn 1,364 Mn 301 Mn 192 Mn Revenue Adjusted EBITDA1 Operational EBITDA2 Profit before Tax3 Adjusted PAT4 Margins Margi
Slide 5: HCG Key Highlights: Q2 FY27
HCG Key Highlights: Q2 FY27 HCG Key Highlights: Q2 FY27 HCG delivered revenue of INR 7,318 Mn in Q2FY27, reflecting ~16% YoY growth • Broad-based growth continued across clusters in Q2FY27. Revenue growth was led by volume growth of 9% YoY. ARPP grew by 7%, improvement driven by a favourable payor m
Slide 6: Financial Highlights: Q2 FY27 and H1 FY27
Financial Highlights: Q2 FY27 and H1 FY27 Financial Highlights: Q2 FY27 and H1 FY27 Q2 FY2027 Financial Highlight H1 FY2027 Financial Highlight Revenue Adjusted EBITDA1 Revenue Adjusted EBITDA1 Margin (%) 19.2% 19.7% Margin (%) 18.8% 19.7% +16% +15% +17% +18% 7,318 14,100 6,321 1,425 12,303 2,740 1,
Slide 7: Revenue Mix By Specialty and Payor: H1 FY27
Revenue Mix By Specialty and Payor: H 1 FY27 Specialty Mix Trend Payor Mix : Increasing Share of Cash & TPA Business in Line with Stated Strategy 11% Non Government 13% 12% 12% Oncology 34% 33% 34% 31% 16% 15% 15% 16% OP + Other Medical services Value Travel 2% 2% 19% 20% 20% 3% 2% 8% 20% 8% 8% 8% S
Slide 8: Region-wise Performance Update: South
Region-wise Performance Update: South Revenue Share % +17% +18% 5,706 Vizag 4,884 H1 40% Revenue Gulburga Vijaywada FY27 2,941 (INR Mn) 2,500 Hubli Ongole Shimonga Bangalore Bed Share1 % Q2FY26 Q2FY27 H1FY26 H1FY27 Chennai H1 45% +4% +5% FY27 Overall 62,707 66,019 Volumes 33,104 Q2 FY27 (# of IP Pat
Slide 9: Region-wise Performance Update: West
Region-wise Performance Update: West Revenue Share % +9% +10% 5,623 6,157 Jaipur H1 44% Revenue FY27 2,871 3,147 (INR Mn) Indore Rajkot Ahmedabad Baroda Nagpur Bed Share1 % Bhavnagar Nashik Q2FY26 Q2FY27 H1FY26 H1FY27 Mumbai H1 41% +7% +8% FY27 Overall 59,898 64,933 Volumes 33,144 Q2 FY27 (# of IP P
Slide 10: Region-wise Performance Update: East
Region-wise Performance Update: East Revenue Share % 12% +23% H1 +23% Revenue FY27 (INR Mn) 1,409 1,727 Ranchi 928 753 Kolkata Bed Share1 % Cuttack Q2FY26 Q2FY27 H1FY26 H1FY27 12% H1 +18% +21% FY27 25,334 Overall 20,866 Volumes 13,038 Q2 FY27 (# of IP Patients) 11,066 # of Centres Total Operating Be
Slide 11: Net Debt Position
Net Debt Position Net Debt Position Net Debt (INR Mn) Key Highlights Net Debt Items 30th Sept 2026 31st Mar 2026 31st Mar 2025 • Cash and Equivalents as at 31st March,26 included the Rights issue proceeds of INR 4,250 Mn Borrowings(1) 7,047 8,817 9,814 • Rights issue proceeds were utilized as follow
Slide 12: Pushing the Boundaries of Complex Cancer Care
Pushing the Boundaries of Complex Cancer Care Selected cases demonstrating specialized expertise, multidisciplinary care and precision-led treatment 01 RARE PAEDIATRIC ONCOLOGY 02 ADVANCED PERITONEAL ONCOLOGY 03 PRECISION RADIOSURGERY Limb-saving surgery in a newborn PIPAC + HIPEC in gastric cancer
Slide 13: Awards and Recognitions H1 FY2027
Awards and Recognitions H1 FY2027 #1 Best Single Specialty Hospital in Odisha - Excellence in Oncology Care and Treatment Times Health July 2026 Radio Mirchi – August 2026 Leader in Cancer Care Times Business Awards Andhra Pradesh Best Cancer Institute in Central India, HCG Single Speciality Hospita
Slide 14: HCG: Growth Plans and Strategic Priorities
HCG: Growth Plans and Strategic Priorities 13 www.hcgoncology.com www. h c g o n c o l o g y. c o m
Slide 15: Strategic Progress
Strategic Progress Executing Our Strategy | Building the Foundation for Sustainable Long-Term Value Creation Focus on core oncology Capacity expansion Capital strength Completed Strategic Exit from Milann North Bengaluru Hospital Operational Successfully Completed Rights Issue ✓ Sharpened focu
Slide 16: No. of Operational Beds
Bed Addition: 1,000 beds by FY30, led by 60% brownfield expansion 31st Mar’26 FY27 FY28 & FY29 FY30 FY30 P 2,734 188 Bed addition ~520 Bed addition ~230 Bed addition ~3,680 Capex ~INR 1,500 Mn Capex ~INR 3,000 Mn Capex ~INR 1,000 Mn No. of Operational Beds¹ 92 96 ~180 ~340 ~100 ~130 Greenfield: Nort
Slide 17: Strategic Priorities To Accelerate Long-Term Value Creation
Strategic Priorities To Accelerate Long -Term Value Creation A B C D Optimize Existing Improve Network Enhance Patient Invest in Growth Network Efficiency Experience 1. Build best-in-class talent → 1. Undertake prudent cost 1. Brownfield expansion across 1. Invest in upgrading existing improve case
Slide 18: Q2FY27 / H1FY27 Consolidated Profit & Loss
Q2FY27 / H1FY27 Consolidated Profit Loss (Excluding Milann Fertility Business) Q2FY27 / H1FY27 Consolidated Profit & Loss (Excluding Milann Fertility Business) Q2FY27 Q2FY26 Y-o-Y H1FY27 H1FY26 Y-o-Y Revenues from Operations 7,301.6 6,303.7 14,066.6 12,272.5 Income from Govt. Grant 16.4 16.9 33.5 30
Slide 19: Consolidated Balance Sheet
Consolidated Balance Sheet Consolidated Balance Sheet Balance Sheet - Equities & Liabilities (INR Mn) Sept-26 Mar-26 Balance Sheet - Assets (INR Mn) Sept-26 Mar-26 Equity share capital 1,493.0 1,493.0 Non-Current Assets Other equity 11,992.7 11,826.7 Property, Plant And Equipment 14,739.4 13,927.9 E
Slide 20: Q2FY27 Operational Metrics
Q2FY27 Operational Metrics Key Metrics South West East Consolidated1 Q1FY27 Q2FY27 Q1FY27 Q2FY27 Q1FY27 Q2FY27 Q1FY27 Q2FY27 Bed Capacity 1,483 1,483 1,440 1,445 359 359 3,304 3,322 Operational Beds 1,299 1,299 1,190 1,195 344 351 2,855 2,880 Census Beds2 991 991 1,093 1,098 334 341 2,440 2,465 In-P
Slide 21: HCG: India's Leading Oncology Platform
HCG: India’s Leading Oncology Platform 20 www.hcgoncology.com www. h c g o n c o l o g y. c o m
Slide 22: A Unique Oncology Platform Redefining Comprehensive Cancer Care Treatment
A Unique Oncology Platform Redefining Comprehensive Cancer Care Treatment A Unique Oncology Platform Redefining Comprehensive Cancer Care Treatment Largest oncology-focused hospital chain Focused approach and with a pan-India network 1 4 Tumor Board enabling effective cancer care Preferred destinati
Slide 23: Largest Pan-India Oncology Focused Hospital Chain
1. Largest Pan-India Oncology Focused Hospital Chain 1. Largest Pan -India Oncology Focused Hospital Chain Largest Geographical Reach… 19 /10 26 Number of Cities and No. of states covered1 hospitals3 Jaipur 3k+ 16/19 Ahmedabad Capacity Leading Indore Ranchi Kolkata beds3 positions2 Rajkot Baroda Bha
Slide 24: Preferred Platform for Leading Oncology Specialists
2. Preferred Platform for Leading Oncology Specialists Integrated Oncology Ecosystem Focused Specialty with Scale Clinical Excellence and Academics Integrated Medical, Full time and exclusive Oncology-specific Access to cutting-edge High degree of clinical Surgical & Radiation Strong referral networ
Slide 25: Introducing Latest Medical Technology in Cancer Care
3. Introducing Latest Medical Technology in Cancer Care TRACK RECORD OF BEING 1st TO LAUNCH ADVANCED State-of-the-art Equipment in each modality TECHNOLOGY IN INDIA Total PET CTs : 20 DIAGNOSTICS 2026 MR-LINAC AI- based 2022 RIS PACS Digital PET Digital CT Automated Digital Skyra Tesla 3T Molecular
Slide 26: Tumor Board Approach to Deliver Customized Treatment
4. Tumor Board Approach to Deliver Customized Treatment 4. Tumor Board Approach to Deliver Customized Treatment Spearheaded by Dr. Ajai, who also heads IRC1 of 30+ 17+ years of nation-wide Supplemented by multiple oncologists for Investigator Initiated Research Studies Tumor Boards held weekly local
Slide 27: A Leading Destination for Comprehensive Cancer Care
5. A Leading Destination for Comprehensive Cancer Care From Early Diagnosis and Treatment to Survivorship 5. A Le a d ing De s t ina t ion f or C omp r e he nsive C a nc e r C a r e Fr om E a r ly Dia gnosis a nd T r e a t me nt t o Su r v iv orship Diagnostics Treatment Post Care Genomics and Digit
Slide 28: Unwavering Focus on Improving Mortality and Enhancing Quality of Life
5. Unwavering Focus on Improving Mortality and Enhancing Quality of Life Well researched strategy to minimize disease recurrence Mortality Rate reduced from 3.4% in 2016 to 0.9% in 2025 Comprehensive Approach • Genomics Driven 4x 74% • Molecular Histopathologic Examination • PET CT Scans Increase in
Slide 29: Experienced Board of Directors
6 Experienced Board of Directors 6 Experienced Board of Directors Dr. BS Ajai Kumar Geeta Mathur Founder and Non-Executive Chairman Non-Executive Independent Director Visionary and key driving force of HCG, with an aim to make advanced cancer Experienced finance professional, serving on Boards of As
Slide 30: HCG Shareholding Pattern and Key Shareholders
HCG Shareholding Pattern and Key Shareholders Top Institutional Investors as on 30th September 2026 Public 14% Foreign Institutional Investors 2% Promoters 64% 30th Sep, Domestic 2026 Institutional Investors 20% 29 www.hcgoncology.com * All logos are for representation purpose only and copyright bel
Slide 31: Annexure: Definitions
Annexure: Definitions Key Metrics Definitions Bed Capacity Bed Capacity reflects total beds that can be accommodated in the hospitals Operational / Census Beds Operational beds comprises of Census and non-census beds Census Beds Revenue generating beds including IPD/Ward beds and Chemo beds Non-Cens
Slide 32: About Us
CIN: L15200KA1998PLC023489 About Us: HealthCare Global Enterprises Ltd. For updates and specific queries, please visit www.hcgoncology.com or contact: (HCG), headquartered in Bengaluru, is the largest provider of cancer care in India. Through its network of 26 hospitals across India and Kenya, Healt
Slide 33: Thank You
THANK YOU www.hcgoncology.com www. h c g o n c o l o g y. c o m
HealthCare Global Enterprises — Q2 FY2027 Earnings Presentation on 6ix